The Wellness Department offers cancer testing using different methods, including ColorTrue (for color cancer genes) and BreastTrue (breast cancer genes).
ColoTrue® is a 13-gene hereditary cancer panel for individuals and families with features suggestive of hereditary colorectal cancer. This panel includes full sequencing analysis of 13 genes. This test also offers site-specific analysis of the MDM2–SNP309 allele. A pathogenic variant in any of these genes warrants consideration of increased colorectal cancer surveillance.
Many of the genes tested in ColoTrue® are also associated with other cancers and hereditary syndromes.
BreastTrue® High Risk Panel is a next-generation sequencing test that detects mutations in eight high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2. In addition, the test includes deletion/duplication analysis of the BRCA1/2 genes by MLPA.
Recent studies of breast cancer survivors have shown that approximately 70 percent of the mutations identified were BRCA1/2 mutations. Approximately 4 percent had germline mutations in other cancer-susceptibility genes, including high-risk genes. These additional high-risk genes include CDH1, CHEK2, PALB2, PTEN, STK11, and TP53. Pathway Genomics’ BreastTrue®High Risk Panel analyzes all of these genes.
BreastTrue® High Risk Panel: https://www.pathway.com/breasttrue/
Send this to friend